Laurus Labs
Laurus Labs is an Indian pharma and biotech company headquartered in Hyderabad, with its manufacturing plants located at Visakhapatnam, Hyderabad and Bengaluru. Its focus areas include active pharma ingredients, finished dosage forms, synthesis and biotechnology.

Laurus Labs manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.

Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest HiPotent API capacities in India The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS, and hydroxychloroquine tablets, which are used to treat certain types of malaria.

In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19.

The company has eight manufacturing facilities located in Visakhapatnam Hyderabad and Bengaluru. The R&D centres are based in Hyderabad, Visakhapatnam and United States. 
Q1361
Hyderabad
LOC
Q200016
Visakhapatnam
LOC
Q1355
Bengaluru
LOC
Q85757327
Dolutegravir/lamivudine/tenofovir
UNK
Q12199
HIV/AIDS
DIS
Q421094
hydroxychloroquine
Concept
Q12156
malaria
Concept
Q84263196
COVID-19
Concept
Q96387060
Laurus Labs
UNK
Q96387060
Laurus Labs
UNK
Q96387060
Laurus Labs
UNK
Q96387060
Laurus Labs
UNK
2020-03-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
March 2020
DATE
-19^^http://www.w3.org/2001/XMLSchema#decimal
-19
NUMBER
medical condition treated